Go Pro
NASDAQ:MLTX

MoonLake Immunotherapeutics Q2 2026 Earnings Report

MoonLake Immunotherapeutics logo
$17.04 -1.22 (-6.68%)
As of 03:00 PM Eastern
This is a fair market value price provided by Massive. Learn more.

MoonLake Immunotherapeutics EPS Results

Actual EPS
-$0.84
Consensus EPS
-$0.92
Beat/Miss
Beat by +$0.08
One Year Ago EPS
N/A

MoonLake Immunotherapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

MoonLake Immunotherapeutics Announcement Details

Quarter
Q2 2026
Time
Before Market Opens
Conference Call Date
Monday, August 10, 2026
Conference Call Time
7:00AM ET

MoonLake Immunotherapeutics Earnings Headlines

Your $29.97 book is free today
Why Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options can give you up to 12 times the leverage of stocks — with a fraction of the capital tied up. This free guide lays it all out in plain English — from A to Z, with step-by-step examples you can follow in your own account.tc pixel
MoonLake reports positive Phase 3 PsA data and $537 million cash
MoonLake Immunotherapeutics GAAP EPS of -$0.84
See More MoonLake Immunotherapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like MoonLake Immunotherapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on MoonLake Immunotherapeutics and other key companies, straight to your email.

About MoonLake Immunotherapeutics

MoonLake Immunotherapeutics (NASDAQ:MLTX), a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was incorporated in 2020 and is headquartered in Zug, Switzerland.

View MoonLake Immunotherapeutics Profile